WELCOME to Stu's Views and MS News

Key-Note: Our live MS educational seminars average 65 people per educational program. SINCE our first program in February 2010, we have hosted more than 120 educational programs.

Register at our website (MS Views and News) to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries. Visit MS Views and News.org

WATCH OUR Multiple Sclerosis archived MS EDUCATIONAL VIDEOS by Topic. Click: www.youtube.com/msviewsandnews

Be Empowered with Beneficial MS Information

Scroll to view all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specific information.

===================================================================

Wednesday, November 14, 2012

Nuron closing in on new treatment for relapsing MS


Tuesday, November 13, 2012
Nuron Biotech Inc. said Tuesday it has completed enrollment of 500 patients for a pivotal phase-III study evaluating the safety and effectiveness of the company’s experimental multiple sclerosis treatment.
Phase-III studies are typically the last hurdle a drug developer must clear before seeking approval for a new drug candidate.
Nuron, an Exton, Pa., specialty biologics and vaccines company, is developing NU100 to treat relapsing remitting multiple sclerosis.
Shankar Musunuri, the company’s founder and CEO, said it expects to complete the study in late 2013.
The company hopes to use the results of the study to support the filing of a European marketing authorization application.
Source: BizJournals

..


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.

No comments: